Indexado en

Licencia y uso

Citaciones

Cited 7 times in

Cited 6 times in

Cited 4 times in

Cited 6 times in

Altmetrics

Grant support

Dr. Rodriguez-Sureda is supported by the Centre for Biomedical Network Research on Rare Diseases (CIBERER) from Instituto de Salud Carlos III. The study was supported in part by grants from Fondo de Investigaciones Sanitarias (FIS PI12/00851 and FIS PI13/01449). The samples used in this Project were provided by the Hospital Clinic-IDIBAPS Biobank and Biobanc HUVH with an appropiate ethical approval. We are grateful to Miss C. O'Hara for her help in editing the English language in the original manuscript.

Análisis de autorías institucional

Compartir

Increased secretory sphingomyelinase activity in the first trimester of pregnancy in women later developing preeclampsia: a nested case-control study

Publicado en:Biological Chemistry. 397 (3): 269-279 - 2016-03-01 397(3), DOI: 10.1515/hsz-2015-0266

Autores: Rodriguez-Sureda, Victor; Crovetto, Francesca; Triunfo, Stefania; Sanchez, Olga; Crispi, Fatima; Llurba, Elisa; Gratacos, Eduard; Figueras, Francesc; Dominguez, Carmen

Afiliaciones

Resumen

The pathogenic basis of abnormal placentation and dysfunction in preeclampsia (PE) is highly complex and incompletely understood. Secretory sphyngomyelinase activity (S-ASM) was analyzed in plasma samples from 158 pregnant women developing PE and 112 healthy pregnant controls. Serum PlGF, sFlt-1, s-Endoglin and sVCAM were measured. Results showed S-ASM activity to be higher in women who later developed PE than in those with uncomplicated pregnancies (40.6% and 28.8% higher in the late- and early-onset groups, respectively). Plasma S-ASM activity correlated significantly with circulating markers of endothelial damage in the late-PE group (endoglin and sVCAM-1), with plasma cholesterol and total lipid levels. However, these significant associations were not observed in the early-PE or control groups. This work provides the first evidence of significantly elevated circulating S-ASM activity in the first trimester of pregnancy in women who go on to develop PE; thus, it may be deduced that the circulating form of ASM is biologically active in PE and could contribute to promoting endothelial dysfunction and cardiovascular programming. Plasma S-ASM measurement may have clinical relevance as a further potential biomarker contributing to the earliest identification of women at risk of developing preeclampsia.

Palabras clave